title: Capecitabine dosing is not yet optimized for breast cancer.
authors.forename: C
authors.initials: C
authors.lastname: Hudis
authors.forename: T
authors.initials: T
authors.lastname: Traina
authors.forename: L
authors.initials: L
authors.lastname: Norton
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D011355:Prodrugs / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil